GSK Tries to Mimic Real-World Biotech
Executive Summary
Not satisfied with its R&D experiments to date, GSK has taken its most radical step yet toward re-creating biotech within its walls: even smaller units complete with investment boards occupied by external VCs and CEOs and milestone-based funding and external VCs.
You may also be interested in...
GSK Woes Raise Big Pharma R&D Question
GSK's various thwarted efforts to boost productivity through R&D revamps begs the question whether big pharma should be trying to do in-house discovery and early development at all.
Rebuilding Big Pharma R&D: An Interview With GSK’s Ian Tomlinson
GlaxoSmithKline’s DPU model is industry’s most radical attempt to apply the lessons – and the pressures – of working in small biotech environments. BD and biopharma head Ian Tomlinson discusses what went wrong, and what GSK thinks it’s now doing right.
GSK Says R&D Productivity Up, But Story Is About Culture, Not Numbers
At its latest R&D review, GSK has culled three of its biotech-like discovery performance units and created four new ones. But less important than the numbers is the new culture, claims CEO Andrew Witty